Table 2

Invasive ovarian and tubal cancers that occurred during surveillance.

BRCA Variant	Age range at diagnosis (yr)	Cancer site and histotype	FIGO stage, grade	CA125 at start of abnormal episode / at time of surgery in occult cases (U/ml)	ROCA score at start of abnormal episode / at time of surgery in occult cases	Transvaginal ultrasound scan result	Interval between abnormal ROCA test and surgery (days)	Interval between last ALDO screen and diagnosis (screen negative cases only) (days)	Extent of cytoreduction	Surgical complexity score*
Prevalent screen-detected cancers (n=3) For these cases, ultrasound scan result is at time of referral.
BRCA2	50–54	C57 Serous	2a, high grade	20.6	1:589	Normal	40	NA	Complete	2
BRCA2	60–64	C56 Serous	3aii, high grade	133.0	1:13	Normal	28	NA	Complete	4
BRCA1	45–49	C57 Serous	3c, high grade	75.6	1:187	Abnormal	71	NA	Incomplete (<1 cm deposits on rectum and bladder)	5
Incident screen-detected cancers (n=3) For these cases, ultrasound scan result is at time of referral.
BRCA1	40–44	C57 serous	1a, high grade	26.5	1:495	Normal	30	NA	Complete	4
BRCA1	35–39	C56 Serous	3b, high grade	76.7	1:33	Abnormal	37	NA	Complete	5
BRCA 1	55–59	C56 Serous	4b, high grade	9.1	1:463	Normal	43	NA	Complete	7
Occult cancers diagnosed within 365 days of prior screen (n=2) For these cases, ultrasound scan result pre-RRSO is by definition normal.
BRCA1	40–44	C57 Serous	1a, high grade	16.0	1:2509	Normal	N/A	39	Complete	4
BRCA1	40–44	C57 Serous	1a, high grade	6.2	1:5324	Normal	N/A	6	Complete	4
Cancers diagnosed in participants with no surveillance (n=2)
BRCA2	40–44	C56 Serous	3c, high grade	N/A	N/A	Normal	N/A	N/A	Incomplete (deposits on hemi diaphragm and omentum)	≥2†
BRCA2	40–44	C56 Serous	3c, high grade	N/A	N/A	CT scan only: Abnormal	N/A	N/A	Complete	8

None of the participants diagnosed with invasive ovarian or tubal cancer had a prior salpingectomy.
C56 ovarian cancer (excluding borderline ovarian tumours in this table).
C57 fallopian tube cancer.
*Surgical complexity score according to Aletti et al.13: 1–3 low, 4–7 intermediate, >7 high.
†Participant had laparoscopic assisted vaginal hysterectomy and BSO with omental and peritoneal biopsies followed by chemotherapy. Further clinical information not available.
ALDO, Avoiding Late Diagnosis of Ovarian Cancer; BSO, Bilateral Salpingo-oophorectomy; FIGO, International Federation of Gynecology and Obstetrics; N/A, not applicable; ROCA, Risk of Ovarian Cancer Algorithm.